RT Journal Article
SR Electronic
T1 Low-grade Fibromyxoid Sarcoma: Treatment Outcomes and Efficacy of Chemotherapy
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 239
OP 245
DO 10.21873/invivo.11766
VO 34
IS 1
A1 CHAMBERLAIN, FLORENCE
A1 ENGELMANN, BODIL
A1 AL-MUDERIS, OMAR
A1 MESSIOU, CHRISTINA
A1 THWAY, KHIN
A1 MIAH, AISHA
A1 ZAIDI, SHANE
A1 CONSTANTINIDOU, ANASTASIA
A1 BENSON, CHARLOTTE
A1 GENNATAS, SPYRIDON
A1 JONES, ROBIN L.
YR 2020
UL http://iv.iiarjournals.org/content/34/1/239.abstract
AB Background: Low-grade fibromyxoid sarcoma (LGFMS) is a rare sarcoma subtype with a generally indolent pattern of clinical behaviour, but treatments for advanced disease are limited. Patients and Methods: A retrospective search of a prospectively maintained institutional database identified 102 patients treated from December 1994 to August 2018. We evaluated the outcome of patients and the efficacy and safety of non-surgical therapies in LGFMS. Results: Ninety-four out of 102 (92.2%) underwent primary resection, seven (6.9%) were treated with systemic therapy and one (1.0%) is currently being treated with pre-operative radiotherapy. The RECIST 1.1 response rate to first-line chemotherapy was 0%, and median progression-free survival was 1.84 months (95% confidence intervaI=0.10-3.6 months). Conclusion: Conventional systemic therapy has limited efficacy in advanced LGFMS.